CCI-779 in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have
advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
National Cancer Institute (NCI) University of Texas Wyeth is now a wholly owned subsidiary of Pfizer